111 Capital Has $2.18 Million Stake in Eli Lilly and Company $LLY

111 Capital increased its holdings in Eli Lilly and Company (NYSE:LLY) by 210.4% in the fourth quarter, Holdings Channel reports. The institutional investor owned 2,030 shares of the company’s stock after buying an additional 1,376 shares during the period. 111 Capital’s holdings in Eli Lilly and Company were worth $2,182,000 at the end of the most recent reporting period.

Other institutional investors have also recently modified their holdings of the company. Lowe Brockenbrough & Co. Inc. raised its holdings in shares of Eli Lilly and Company by 26.0% during the fourth quarter. Lowe Brockenbrough & Co. Inc. now owns 8,469 shares of the company’s stock valued at $9,101,000 after purchasing an additional 1,749 shares during the period. MCF Advisors LLC raised its holdings in shares of Eli Lilly and Company by 10.8% during the fourth quarter. MCF Advisors LLC now owns 2,765 shares of the company’s stock valued at $2,971,000 after purchasing an additional 270 shares during the period. Closed End Fund Advisors Inc. acquired a new position in shares of Eli Lilly and Company during the fourth quarter valued at about $430,000. First Command Advisory Services Inc. raised its holdings in shares of Eli Lilly and Company by 68.7% during the fourth quarter. First Command Advisory Services Inc. now owns 2,335 shares of the company’s stock valued at $2,509,000 after purchasing an additional 951 shares during the period. Finally, Invst LLC raised its holdings in shares of Eli Lilly and Company by 103.7% during the fourth quarter. Invst LLC now owns 6,864 shares of the company’s stock valued at $7,377,000 after purchasing an additional 3,494 shares during the period. 82.53% of the stock is currently owned by institutional investors.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: CVS Caremark reversed its earlier exclusion and will now cover Eli Lilly’s Zepbound, a meaningful reimbursement win that could expand patient access and bolster obesity-drug sales. Article Title
• Positive Sentiment: WeightWatchers Med+ is now available through LillyDirect, reinforcing Lilly’s distribution ecosystem and strengthening its leadership in chronic weight management. Article Title
• Positive Sentiment: Lilly announced a new Phase 2b obesity trial for macupatide–eloralintide, adding another potential growth driver to its weight-loss pipeline beyond current GLP-1 products. Article Title
• Positive Sentiment: Jim Cramer highlighted Lilly as a potential winner against competitors, with attention on its new pill version of its weight-loss drug and broader competitive advantages. Article Title
• Positive Sentiment: Analysts and market commentary continue to frame LLY as a long-term winner, citing strong execution, deal-making, and diversification efforts beyond obesity drugs. Article Title
• Neutral Sentiment: Lilly also received coverage around its Phase 3 Libretto-432 cancer study and a $1.9 billion Ascidian partnership, both of which support the pipeline but are longer-term in nature. Article Title
• Neutral Sentiment: Broader health-care sector commentary and stock-screen articles were generally supportive, but they are less likely to be a direct driver of LLY’s move than the CVS and pipeline news. Article Title

Wall Street Analysts Forecast Growth

LLY has been the topic of several research reports. Freedom Capital upgraded shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Tuesday, February 10th. Bank of America boosted their target price on shares of Eli Lilly and Company from $1,133.00 to $1,251.00 and gave the stock a “buy” rating in a research report on Tuesday, May 26th. Berenberg Bank upped their target price on shares of Eli Lilly and Company from $950.00 to $1,050.00 and gave the stock a “hold” rating in a report on Thursday, February 19th. Royal Bank Of Canada reaffirmed an “outperform” rating on shares of Eli Lilly and Company in a research report on Thursday, May 21st. Finally, Jefferies Financial Group lifted their price target on Eli Lilly and Company from $1,300.00 to $1,330.00 in a research note on Thursday, May 21st. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Eli Lilly and Company has a consensus rating of “Moderate Buy” and an average target price of $1,227.00.

Eli Lilly and Company Price Performance

LLY stock opened at $1,133.15 on Friday. The firm’s 50-day moving average price is $974.59 and its two-hundred day moving average price is $1,013.04. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,166.29. The stock has a market capitalization of $1.07 trillion, a price-to-earnings ratio of 40.25, a PEG ratio of 1.23 and a beta of 0.53. The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The firm had revenue of $19.80 billion for the quarter, compared to analysts’ expectations of $17.82 billion. During the same quarter in the previous year, the company earned $3.34 earnings per share. The company’s revenue for the quarter was up 55.5% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, equities analysts predict that Eli Lilly and Company will post 35.8 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be given a $1.73 dividend. The ex-dividend date is Friday, May 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. Eli Lilly and Company’s payout ratio is presently 24.58%.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.